Row over SMA drug distribution in Keralam unwarranted, say experts
Experts and hospital authorities rejected a dispute over the distribution of an SMA drug at a clinic in Keralam. Parents had alleged that a free medicine was experimental, while the hospital said it was the Indian generic version of risdiplam.
A controversy over the distribution of medicine for spinal muscular atrophy at a Keralam hospital clinic was described as unwarranted by experts and hospital authorities. Parents of children with SMA had claimed that the medicine supplied free of cost was an experimental drug, raising concerns about the safety and suitability of the treatment.
SAT Hospital authorities disputed that account. They said the medicine provided at the clinic was the generic version of risdiplam, the original formula developed by Roche, and not an experimental substance. The distinction is important because the medicine was already in established use, although questions about quality, sourcing and patient counselling can still influence how families understand a treatment.
For readers in Kerala, the dispute matters because it affects confidence in free medical care for children with serious conditions. Families making treatment decisions need clear information about the origin, regulatory status and known effects of a medicine, especially when they are asked to rely on a hospital programme offered at no cost.
Comments 0